EAM
AUTL

Exome Asset Management’s Autolus Therapeutics AUTL Stock Holding History

Exome Asset Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-839,472
Closed -$2.92M – 63
2024
Q2 		$2.92M Buy
+839,472
New +$3.62M 2.6% 13

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Exome Asset Management's AUTL Position: Q3 2024 in Review

Exome Asset Management sold out of Autolus Therapeutics (AUTL) in Q3 2024, closing a stake of 839,472 shares — an estimated $2.92M sold.

Exome Asset Management first reported a position in AUTL in Q2 2024 and held it in 1 quarter. The position peaked at $2.92M in Q2 2024. 101 funds tracked by Wall St. Rank hold AUTL as of Q3 2024.

  • Exome Asset Management reported no remaining Autolus Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Exome Asset Management sold 839,472 Autolus Therapeutics shares in Q3 2024, an estimated $2.92M.
  • Exome Asset Management first reported a position in Autolus Therapeutics in Q2 2024 and held it in 1 quarter.
  • Exome Asset Management's Autolus Therapeutics position peaked at $2.92M in Q2 2024.
  • 101 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2024.

Based on Exome Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.